BARICADE-PRESERVE

• People diagnosed with type 1 diabetes within the last 100 days
• People aged between 1 and 35 years of age
• Able to attend study visits at Austin Hospital (Heidelberg) or Royal Melbourne Hospital (Parkville), (Royal Children’s Hospital coming soon)

• Whether baricitinib can help in managing newly diagnosed type 1 diabetes
• Whether baricitinib works better than a placebo (a placebo is an inactive or “pretend” study drug)
• The possible side effects people might have when taking baricitinib

In this study 2 out of every 3 people will receive baricitinib and 1 out of every 3 people will receive a placebo. Baricitinib (and the study placebo) is taken in tablet form or as a liquid for those who cannot swallow tablets.

If you meet the criteria to enter this clinical trial, the study treatment will be given for at least 52 weeks (1 year). To monitor your health closely, you will need to attend the clinic for study related visits approximately 10 times over 14 months.

At each visit the study team will monitor your blood glucose levels, insulin production and overall health to ensure that you are well and that the study treatment is safe and effective.

This study is important to people with type 1 diabetes because this medication might be able to maintain the undamaged insulin making cells allowing the person to keep making some of their own insulin. This has been shown to make the management of type 1 diabetes with injected insulin easier.